



Expanding access to medicines and health technologies

Turning innovation into access for people
in low- and middle-income countries.

medicinespatentpool.org



Who we are

Founded by Unitaid in 2010, the Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, innovative medicines and other health technologies for people in need in low- and middle-income countries (LMICs).

We work at the intersection of innovation, manufacturing and public health, partnering with civil society, governments, pharmaceutical companies, generic manufacturers, and international organisations. By bringing these actors together, MPP helps translate medical innovation into real-world access and impact, across countries and disease areas.



What we do

MPP helps close persistent access gaps by supporting the earlier availability, affordability and sustainable supply of priority health products.

Through public health-oriented voluntary licensing and technology transfer, MPP works with innovators and manufacturers to enable the development, production and scale-up of quality-assured medicines and health technologies in countries where access would otherwise be delayed or limited. Our work spans infectious diseases, non-communicable diseases (NCDs), maternal and child health, pandemic preparedness and emerging health technologies.

Our non-exclusive, transparent licensing model supports competition, strengthens supply resilience and enables sustainable access over time, while recognising the role of innovation.




How we work: A public health-driven model

MPP's approach combines licensing expertise, implementation support and partnership-based delivery to help ensure that innovation reaches people who need it most.

In practice, this means:

- Identifying priority products with strong potential public health impact
- Negotiating transparent, non-exclusive licences with innovators and technology holders
- Working with qualified manufacturers across regions
- Supporting product development, regulatory progress and supply
- Facilitating technology transfer where needed, and the strengthening of local and regional manufacturing
- This model helps accelerate access, support competition, strengthen supply resilience and enable sustainable scale-up over time

Our business model






Key features of MPP licences

The terms and conditions in MPP licences seek to improve treatment and health product options for the broadest number of people living in LMICs and are negotiated on a case-by-case basis with each innovator.



MPP's support to partners



Our focus areas



Biotherapeutics

Beyond our continued work on small molecules, we are increasingly focusing our efforts to foster access to key biotherapeutics, such as monoclonal antibodies and recombinant proteins. MPP supports earlier and more affordable access by adapting its licensing and technology transfer approaches to complex products.



Local and regional manufacturing

Diversified and sustainable manufacturing is essential for long-term access and supply security. MPP supports local and regional manufacturing through licensing and technology transfer, including through the MedSuRe project, funded by Unitaaid and the European Union and led by United States Pharmacopeia (USP).



Pandemic preparedness and response

MPP supports more equitable preparedness and response by integrating voluntary licensing and technology transfer into efforts that enable geographically diversified manufacturing and faster access to health products during future health emergencies.



Technology transfer

Technology transfer enables access to complex health technologies. MPP supports knowledge and skills' transfer between partners, including through the WHO-MPP mRNA Technology Transfer Programme, to help manufacturers build capacity and support sustainable production of quality-assured products.



Upstream access

MPP engages early with partners to help embed access considerations in licensing and funding arrangements, supporting more equitable access as health technologies progress through development, regulatory approval and scale-up.

Our prioritisation framework


Focusing on public health impact

MPP deploys a transparent, public health-driven prioritisation framework to identify medicines and health technologies where intervention could lead to meaningful improvements in access, affordability and health outcomes.

This work helps guide engagement with innovators and partners and spans a wide range of disease areas and technology types.



Priority and watchlist products are published and regularly updated.



Argentina Sinergium Biotech	Indonesia Biofarma BrightGene (PT Anvita Pharma) Kimia Farma
Bangladesh Beximco Incepta Vaccine Ltd	Kenya Biovax
Brazil Bio-Manguinhos/Fiocruz	Mexico Neopharma
China Apeloa Charioteer Desano China Fosun Huahai Jiuzhou	Nigeria Biovaccines Nigeria Ltd
Egypt BioGeneric Pharma S.A.E	Pakistan National Institute of Health Remington
India Arene Aurobindo BiologicalE Cipla DRL Emcure Eugia Hetero Laurus Lupin Macleods Mangalam Microlabs MSN Natco Strides Sun Viatris (Mylan) USV Zydus	Senegal Institut Pasteur de Dakar
	Serbia Institut Torlak
	South Africa Adcock Ingram Biovac
	South Korea Celltrion Dongbang Futuretech
	Tunisia Institut Pasteur de Tunis
	Ukraine Darnytsia
	Vietnam Polyvac Stellapharm
Product developers	
Biotech Africa Codix Bio	TB Alliance Gates MRI

Partnerships with generic manufacturers and product developers by country

Since its foundation, MPP has worked with 93 generic manufacturers, product developers and mRNA partners across 24 countries to help expand access to priority health products. The map and list show the generic manufacturers and product developers that currently hold an active sublicense with MPP and mRNA Programme partners, reflecting ongoing partnerships that support the development, manufacture and supply of quality-assured medicines and health technologies.

As of May 2026, MPP currently works with 53 generic manufacturers, product developers and mRNA Programme Partners, across 18 countries



Open digital tools

MPP provides free, publicly available tools that support informed decision-making across the access pathway:

MedsPaL

THE MEDICINES PATENTS AND LICENCES DATABASE

Database providing information on the intellectual property status of key health technologies and products across countries.

- Medicines:** Patented medicines on the WHO EML and medicines prioritised for MPP licensing
- Vaccines:** Selected COVID-19 vaccines worldwide, evolving to cover other key patented vaccines
- Technologies:** Long-acting technologies included in LAPaL (see below)

medspal.org



LAPaL

THE LONG-ACTING THERAPEUTICS PATENTS AND LICENCES DATABASE

A dedicated portal on long-acting therapies, providing information on the technical characteristics and intellectual property status of a wide range of these therapies and their potential applications, notably in the fields of HIV, viral hepatitis, tuberculosis and respiratory syncytial virus (RSV).

lapal.ch




AccessPaL

ACCESS PATHWAYS AND LANDSCAPE TRACKER

An interactive tool combining a map and table that monitors progress in the development, regulatory approval and supply of health products licensed through MPP, as well as top-level information on the patent and licensing status of these products by country.

accesspal.org





Impact estimates are based on country-level modelling of access enabled through MPP supported pathways contrasting MPP's contribution to alternative scenarios where key WHO-recommended medicines would not have been available through MPP licences¹.

Our impact

MPP's work has supported access to medicines and health technologies across countries and disease areas.

Selected highlights (2010-2025):

23 patent holders
have signed agreements with MPP

93 manufacturers, product developers and mRNA Programme partners engaged

62+ Bn
doses of treatment supplied

148 countries
reached


US\$ 2.6 Bn
in estimated savings

6.7 Mn
additional patient-years treated through MPP licensing

¹ The MPP's impact assessment methodology was developed with technical support from Cambridge Economic Policy Associates (CEPA) and funding from Unitaid. The methodology was published in The Lancet Public Health in 2021 in a research article entitled *The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study*

MPP Agreements 2010 – 2026

Partnership with innovators across different disease areas



Programme guiding principles:



Equitable access to mRNA technologies suitable for pandemic response.



Create value and share intellectual property through **open access to innovation**.



Promote sustainable capacity to produce mRNA vaccines with **coherent policies and adequate investments**.

mRNA Technology Transfer Programme



Co-led by WHO and MPP, the Programme was set up in 2021 to address the inequalities in access to vaccines in LMICs that emerged during the COVID-19 pandemic.

Programme Goal and Global Collaboration


Launched to help address global inequities in access to life-saving vaccines and therapeutics, the Programme supports the development of sustainable mRNA research, development, and manufacturing capacity in LMICs. Over the years, it has evolved into a growing global network of manufacturers, research institutions and innovation partners.

WHO has selected 15 manufacturers to join the mRNA Technology Transfer Programme with Afrigen who is the center for mRNA technology development and tech transfer:



mRNA Programme Partners' Disease Targets by Region

As part of the mRNA Technology Transfer Programme, the creation of R&D consortia focuses on developing vaccines for diseases relevant to LMICs. These consortia bring together Programme Partners, companies, research centres, and universities to collaborate on the development of vaccines and therapeutics using the mRNA platform.





The Medicines Patent Pool was founded and is funded by Unitaid.

GENEVA:

Rue de Varembe 7, fifth floor
1202 Geneva, Switzerland
Tel. +41 (0)22 533 50 50

office@medicinespatentpool.org

Other funders:



Coefficient
Giving



medicinespatentpool.org

June 2026

MUMBAI:

Unit #1006, A wing, Kanakia Wall Street
Chakala, Andheri-Kurla Road
Andheri (east), Mumbai 40009
Maharashtra, India
india@medicinespatentpool.org